Literature DB >> 10689210

Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia.

H Ariffin1, P Navaratnam, M Mohamed, A Arasu, W A Abdullah, C L Lee, L H Peng.   

Abstract

OBJECTIVES: To evaluate prevalence of ceftazidime-resistant Klebsiella pneumoniae (CRKP) in the pediatric oncology unit of University Hospital, Kuala, Lumpur, and to identify differences between febrile neutropenic pediatric patients with CRKP and ceftazidime-sensitive K. pneumoniae (CSKP) bacteremia.
MATERIALS AND METHODS: Febrile neutropenic patients treated between January 1996 and December 1997 at the pediatric oncology unit of University Hospital, Kuala Lumpur, were prospectively studied. Empirical antibiotic therapy consisted of ceftazidime and amikacin. Those who developed K. pneumoniae bacteremia were identified, and clinical features analyzed. Ceftazidime-resistance was documented via disk-diffusion testing. Production of extended-spectrum beta-lactamase (ESBL) was inferred on the basis of synergy between ceftazidime and amoxicillin-clavulanic acid. The different features between the two groups and variables associated with the development of CRKP bacteremia were analyzed using chi-square and t-tests and calculation of odds ratios. A multivariate analysis was used to identify independent factors for CRKP development.
RESULTS: Ceftazidime-resistance was seen in 51.6% of all K. pneumoniae isolates, and all these isolates were inferred to be ESBL producers. All isolates were sensitive to imipenem. Susceptibility to gentamicin was 90.5%. The mean continuous hospital stay prior to the detection of bacteremia was 13.7 days overall, but significantly longer in the CRKP group (21.9 d) compared to the CSKP group (4.3 d) (P = 0.003). Children with CRKP were more likely to have received antibiotics in the 2 weeks prior to detection of bacteremia (87.5% of cases) than the CSKP group (20.0% of cases) (P = 0.0008). Sepsis-related mortality was higher in those with CRKP (50.0%) than in the CSKP group (13.3%) (P = 0.02). Patients who did not receive CRKP-directed antibiotics within 48 hours of admission were more likely to have a fatal outcome than those who did (P = 0.009). Logistic regression analysis identified use of third-generation cephalosporins 2 weeks prior to presentation and a hospital stay of 2 weeks or more as independent risk factors for development of CRKP.
CONCLUSIONS: More than half of total K. pneumoniae isolated from blood cultures in the unit were ceftazidime-resistant. Children with febrile neutropenia with prolonged hospital stay and recent prior antibiotic exposure are at high risk of developing CRKP bacteremia. Mortality was significantly higher in this group. Early commencement of appropriate antibiotics (e.g., imipenem with or without gentamicin), according to susceptibility study results, may be beneficial in such circumstances.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10689210     DOI: 10.1016/s1201-9712(00)90061-4

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  22 in total

1.  Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae.

Authors:  Mitchell J Schwaber; Shiri Navon-Venezia; Keith S Kaye; Ronen Ben-Ami; David Schwartz; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

2.  Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients.

Authors:  D Averbuch; E Horwitz; J Strahilevitz; P Stepensky; N Goldschmidt; M E Gatt; M Y Shapira; I B Resnick; D Engelhard
Journal:  Infection       Date:  2013-05-08       Impact factor: 3.553

3.  Epidemiology of infections due to extended-spectrum Beta-lactamase-producing bacteria in a pediatric intensive care unit.

Authors:  Kim W Benner; Priya Prabhakaran; Autumn S Lowros
Journal:  J Pediatr Pharmacol Ther       Date:  2014-04

Review 4.  Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update.

Authors:  Bradley A Warady; Sevcan Bakkaloglu; Jason Newland; Michelle Cantwell; Enrico Verrina; Alicia Neu; Vimal Chadha; Hui-Kim Yap; Franz Schaefer
Journal:  Perit Dial Int       Date:  2012-06       Impact factor: 1.756

5.  Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome.

Authors:  Yun-Kyung Kim; Hyunjoo Pai; Hoan-Jong Lee; Su-Eun Park; Eun-Hwa Choi; Jungmin Kim; Je-Hak Kim; Eui-Chong Kim
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Non-fermentative Gram-negative rods bacteremia in children with cancer: a 14-year single-center experience.

Authors:  D Averbuch; C Avaky; M Harit; P Stepensky; I Fried; T Ben-Ami; V Temper; Y Peled; H Troen; R Masarwa; W Abu Ahmad; M Weintraub; S Revel-Vilk; D Engelhard
Journal:  Infection       Date:  2017-02-15       Impact factor: 3.553

Review 7.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

8.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

9.  Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: experience of single center in southeast of Turkey.

Authors:  Selda Aslan; Elvan Caglar Citak; Reyhan Yis; Suleyman Degirmenci; Dilek Arman
Journal:  Indian J Microbiol       Date:  2011-08-13       Impact factor: 2.461

10.  Risk of acquiring extended-spectrum β-lactamase-producing Klebsiella species and Escherichia coli from prior room occupants in the intensive care unit.

Authors:  Adebola O Ajao; J Kristie Johnson; Anthony D Harris; Min Zhan; Jessina C McGregor; Kerri A Thom; Jon P Furuno
Journal:  Infect Control Hosp Epidemiol       Date:  2013-05       Impact factor: 3.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.